Plain-English translation of NCT05669339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether three medications — , , and — work better together when doses are personalized for each patient with advanced liver cancer. The study uses artificial intelligence and blood tests to find the safest and most effective dose for you. The goal is to see if this approach improves outcomes while reducing side effects.
Standard treatments for advanced liver cancer have limited effectiveness for some patients. This trial exists to see whether a new combination of medications, customized to each person's body and genetics, might work better and be safer than one-size-fits-all dosing.
You likely qualify if…
You likely don't qualify if…
You will receive three medications by mouth at doses determined especially for you based on blood tests and artificial intelligence analysis. You'll visit the treatment center regularly over about 12 weeks for blood work, scans, and check-ups to measure how well the treatment is working and monitor for side effects. The study team will use blood tests to track cancer markers and watch your liver and kidney function closely.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States